サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1445543

特発性膜性腎症 (IMN) 市場の評価：タイプ (クロラムブシル・アルキル化剤・シクロホスファミド・その他)・用途 (診療所・病院・その他)・地域別の機会および予測 (2017～2031年)

Idiopathic Membranous Nephropathy (IMN) Market Assessment, By Type [Chlorambucil, Alkylating Agents, Cyclophosphamide, Others], By Application [Clinics, Hospitals, Others], By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 228 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
特発性膜性腎症 (IMN) 市場の評価：タイプ (クロラムブシル・アルキル化剤・シクロホスファミド・その他)・用途 (診療所・病院・その他)・地域別の機会および予測 (2017～2031年)
出版日: 2024年03月07日
発行: Market Xcel - Markets and Data
ページ情報: 英文 228 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の特発性膜性腎症 (IMN) の市場規模は、2024年から2031年の予測期間中にCAGR 8.83％で成長し、2023年の2億140万米ドルから、2031年には3億9,618万米ドルの規模に成長すると予測されています。

IMNに対する意識の高まりと、診断ソリューションの値ごろ感を高めるための政府の取り組みが市場に有利な成長機会をもたらしています。これに伴い、IMN患者における併用療法の動向を見極めるための研究活動がますます盛んになっており、これが重要な市場動向として作用しています。市場需要は、高齢化人口の増加、座りがちなライフスタイルの増加、腎疾患の発生率の上昇によってさらに高まっています。

政府の取り組みの高まりが市場の成長を支える

R&D活動を支援するさまざまな政府機関による取り組みの増加が市場に有利な成長機会をもたらしています。IMNのさまざまな患者における薬剤の有効性を明らかにするため、さまざまな調査研究が行われています。

R&D活動の活発化が市場開発を後押し

R&D活動には、イノベーションの促進や新製品の開発促進、既存製品の有効性向上など、さまざまなメリットがあります。また、研究者は併用療法の効果を研究も行っています。中国北京のPeking Union Medical College Hospitalでは、IMNの治療において、RTXとシクロスポリンの併用がRTX単独よりも有効かどうかを調べる介入研究を行っています。IMNの第一選択免疫抑制療法には、安全性プロファイルが優れていることから、リツキシマブ (RTX) またはシクロホスファミドと副腎皮質ステロイドの併用療法が行われています。しかし、リツキシマブ単独療法の長期寛解率は約60％です。シクロスポリンとRTXはポドサイトや免疫系に対する作用が異なり、作用時間も異なるため、特発性膜性腎症の治療には相乗効果が期待されています。

北米が大きな市場シェアを占める

予測期間中は北米地域が市場で大きなシェアを占めると予想されています。この成長は、さまざまな大手参入企業の強い存在感と、この地域のさまざまな研究機関による研究活動の増加に起因しています。米国NIAIDでは、IMN患者を対象に、リツキシマブとベリムマブの静脈内投与による完全寛解導入の有効性を、リツキシマブのみの場合と比較して評価する研究を実施しています。この介入研究では、特発性膜性腎症をリツキシマブとベリムマブの併用で治療した場合、リツキシマブ単独で治療した場合と比較して、腎臓に対する免疫攻撃が効果的に阻止されるかどうかを研究しています。

当レポートでは、世界の特発性膜性腎症 (IMN) の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の特発性膜性腎症 (IMN) 市場の展望

  • 市場規模・予測
  • タイプ別
    • クロランブシル
    • アルキル化剤
    • シクロホスファミド
    • その他
  • 用途別
    • 診療所
    • 病院
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 企業別市場シェア

第5章 世界の特発性膜性腎症 (IMN) 市場の展望：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第6章 市場マッピング

  • タイプ別
  • 用途別
  • 地域別

第7章 マクロ環境と産業構造

  • 需要供給分析
  • 輸出入分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

  • 特許の情勢
  • 規制当局の承認
  • イノベーション/新興技術

第10章 主要企業の情勢

  • 市場リーダー上位5社の競合マトリックス
  • 市場リーダー上位5社の市場収益分析
  • M&A・ジョイントベンチャー (該当する場合)
  • SWOT分析 (参入5社)
  • 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • Pfizer, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Astellas Pharma Inc.
  • GlaxoSmithKline
  • Aspen Global Inc.
  • Baxter Healthcare Corporation
  • Mylan Pharmaceuticals Inc
  • Sigma-Aldrich Corporation
  • Merck & Co., Inc.

第14章 戦略的提言

第15章 当社について・免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 2. Global Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 7. North America Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 8. North America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 9. North America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 10. North America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 12. United States Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 13. United States Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 14. United States Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 15. Canada Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 16. Canada Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 17. Canada Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 18. Canada Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 19. Mexico Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 20. Mexico Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 21. Mexico Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 22. Mexico Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 23. Europe Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 24. Europe Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Europe Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 26. Europe Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 27. Europe Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 29. Germany Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Germany Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 31. Germany Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 32. France Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 33. France Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 34. France Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 35. France Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 36. Italy Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 37. Italy Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 38. Italy Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 39. Italy Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 40. United Kingdom Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 41. United Kingdom Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 42. United Kingdom Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 43. United Kingdom Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 44. Russia Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 45. Russia Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Russia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 47. Russia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 48. Netherlands Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 49. Netherlands Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 50. Netherlands Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 51. Netherlands Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 52. Spain Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 53. Spain Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 54. Spain Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 55. Spain Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 56. Turkey Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 57. Turkey Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 58. Turkey Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 59. Turkey Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 60. Poland Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 61. Poland Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 62. Poland Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 63. Poland Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 64. South America Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 65. South America Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. South America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 67. South America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 68. South America Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 70. Brazil Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Brazil Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 72. Brazil Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 73. Argentina Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 74. Argentina Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 75. Argentina Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 76. Argentina Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 77. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 78. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 79. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 80. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 81. Asia-Pacific Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 82. India Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 83. India Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 84. India Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 85. India Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 86. China Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 87. China Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 88. China Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 89. China Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 90. Japan Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 91. Japan Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Japan Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 93. Japan Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 94. Australia Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 95. Australia Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 96. Australia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 97. Australia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 98. Vietnam Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 99. Vietnam Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 100. Vietnam Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 101. Vietnam Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 102. South Korea Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 103. South Korea Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 104. South Korea Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 105. South Korea Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 106. Indonesia Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 107. Indonesia Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. Indonesia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 109. Indonesia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 110. Philippines Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 111. Philippines Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 112. Philippines Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 113. Philippines Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 114. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 115. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 116. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 117. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 118. Middle East & Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 120. Saudi Arabia Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 121. Saudi Arabia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 122. Saudi Arabia Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 123. UAE Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 124. UAE Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 125. UAE Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 126. UAE Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 127. South Africa Idiopathic Membranous Nephropathy (IMN) Market, By Value, In USD Million, 2017-2031F
  • Figure 128. South Africa Idiopathic Membranous Nephropathy (IMN) Market, By Volume, in Million Units, 2017-2031F
  • Figure 129. South Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Type, 2017-2031F
  • Figure 130. South Africa Idiopathic Membranous Nephropathy (IMN) Market Share (%), By Application, 2017-2031F
  • Figure 131. By Type Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 132. By Application Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 133. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023
目次
Product Code: MX11092

Global idiopathic membranous nephropathy (IMN) market is projected to witness a CAGR of 8.83% during the forecast period 2024-2031F, growing from USD 201.4 million in 2023 to USD 396.18 million in 2031. The growing awareness about idiopathic membranous nephropathy and rising government efforts to increase the affordability of diagnostic solutions are providing lucrative growth opportunities to the market. In line with this, research activities are increasingly being conducted to determine the effects of combination therapy in patients with idiopathic membranous nephropathy, which is acting as a crucial market trend. The market demand is further driven by an increasing aging population, growing adoption of a sedentary lifestyle, and rising rate of renal diseases.

Increasing research activities by different research institutions to understand the effects of different treatments in patients with idiopathic membranous nephropathy is further supporting the market expansion. For instance, Beijing Friendship Hospital is conducting an interventional, randomized, open controlled study to understand the influence of various treatment schemes on the cognitive status of patients suffering from idiopathic membranous nephropathy. The exploration of the possible pathophysiological mechanism is expected to be conducted with the help of brain magnetic resonance imaging technology. The study aims to provide a theoretical basis for enhanced prevention of cognitive impairment and clinical treatment scheme selection and more information about the clinical cognitive status of idiopathic membranous nephropathy. The study is expected to conclude in 2025.

Rising Government Efforts Support Market Growth

Increasing efforts by various government institutes to support research and development activities are providing lucrative growth opportunities to the market. Different research studies are being conducted to determine the efficacy of drugs in different patients with idiopathic membranous nephropathy. The National Natural Science Foundation of China is supporting different research activities for treating idiopathic membranous nephropathy. Various studies have been conducted to demonstrate the efficacy of drugs in patients suffering from idiopathic membranous nephropathy with high or moderate proteinuria, however, systemic comparison has yet to be confirmed. Therefore, a network meta-analysis was performed for comparing the efficacy of idiopathic membranous nephropathy treatments in patients with high and moderate proteinuria, while comparing the risk of adverse events with idiopathic membranous nephropathy regimens.

Increasing Research and Development Activities are Boosting the Market Expansion

Research and development activities offer various benefits, including facilitation of innovation and accelerated development of new products as well as aid in improving the efficacy of existing products. They also allow researchers to study the effects of combination therapy. For instance, Peking Union Medical College Hospital, Beijing, China is conducting an interventional study to determine whether RTX combined with cyclosporine is more effective than RTX alone for treating idiopathic membranous nephropathy. The first-line immunosuppressive therapy of idiopathic membranous nephropathy includes Rituximab (RTX) or cyclophosphamide in combination with corticosteroids due to their superior safety profile. However, the long-term remission rate of Rituximab monotherapy is about 60%. Cyclosporin and RTX are expected to have a synergistic effect for treating idiopathic membranous nephropathy as they have different effects on podocytes and the immune system and different time of action.

North America Accounts for Significant Market Share

North America is expected to account for a significant share of the market over the forecast period. This growth can be attributed to the strong presence of various leading market players and increasing research activities by different research organizations in the region. For instance, the National Institute of Allergy and Infectious Diseases (NIAID) is conducting a study to evaluate the effectiveness of intravenous rituximab and belimumab at inducing complete remission as compared to just rituximab in patients suffering from idiopathic membranous nephropathy. In this interventional study, researchers will evaluate if treating idiopathic membranous nephropathy in combination with rituximab and belimumab will effectively block the immune attacks on kidney in comparison to rituximab alone. Rituximab works by decreasing B cells, they are known to have a role in membranous nephropathy. Upon the removal of these cells, the disease might become less active or even completely inactive. Belimumab works by changing the type of new B cells produced in the body and decreasing the B cells. Belimumab has received approval from the Food and Drug Administration (FDA) for treating systemic lupus erythematosus, whereas rituximab is approved for treating vasculitis, rheumatoid arthritis, and some types of cancer. Treating membranous nephropathy with a combination of rituximab and belimumab has previously not been studied, however the combination has been tested for treating other autoimmune diseases. The study is expected to reach completion in 2030.

Cyclophosphamide Expected to Witness Significant Expansion

Recent studies have shown that alternating glucocorticoid-cyclophosphamide is superior to rituximab for proteinuria remission. RI-CYCLO and STARMEN confirmed the efficacy of glucocorticoid-cyclophosphamide in patients suffering from high-risk membranous nephropathy. For treating high-risk patients, the 2021 KDIGO guidelines recommend initiation of immunosuppressive treatments with cyclophosphamide associated with steroids, calcineurin, or RTX. The only recommended option for treatment in very high-risk patients is corticosteroids plus cyclophosphamide. Potential new strategies for the treatment of idiopathic membranous nephropathy include the utilization of an induction phase with intravenous cyclophosphamide on a monthly basis or a combination of RTX with low-dose cyclophosphamide. These strategies showcased encouraging immunological remission and clinical results, with excellent safety profile.

Hospitals Account for Significant Market Share

Hospitals are expected to account for a significant market share as some patients often face life threatening and severe nephrotic syndrome even while the excretory renal functions are working normally. Various medical college hospitals are conducting studies to understand the effects of different immunosuppressive therapies in patients suffering from idiopathic membranous nephropathy, which is expected to create positive market opportunities. For instance, Peking Union Medical College Hospital, Beijing, China, is conducting an interventional study for comparing the twenty-four-month remissions in idiopathic membranous nephropathy by different immunosuppressive therapies. The investigators designed this study for comparing the efficacy of corticosteroids plus cyclophosphamide with rituximab in treating idiopathic membranous nephropathy. The study is estimated to reach completion in 2027.

Future Market Scenario (2024 - 2031F)

Different research activities are underway in various regions across the globe for determining the tolerability, safety, and efficacy of different treatments for idiopathic membranous nephropathy. For instance, Nagoya University, Nagoya, Japan is conducting an interventional study to confirm the safety and efficacy of intravenous administration of rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome. The clinical study is going to be double-blind, randomized, multi-center, and placebo controlled and is estimated to reach completion in December 2026. Furthermore, various biotech companies, including SynAct Pharma Aps, are also conducting different studies to evaluate the efficacy and pharmacokinetic effects of different treatments in patients with idiopathic membranous nephropathy.

Key Players Landscape and Outlook

Key participants in the idiopathic membranous nephropathy (IMN) market include Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Astellas Pharma Inc., and GlaxoSmithKline. The market is expected to witness significant growth over the forecast period due to rising research and development activities by different market players and the conduct of several clinical trials.

Novartis AG, one of the leading pharmaceutical corporations, received positive results for their phase 3 trials for targeted factor B inhibitor iptacopan. The company plans on initiating discussions with the FDA to receive accelerated approval for iptacopan, whose target indications include idiopathic membranous nephropathy, C3 glomerulopathy, and atypical haemolytic uraemic syndrome.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Idiopathic Membranous Nephropathy (IMN) Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Type
    • 4.2.1. Chlorambucil
    • 4.2.2. Alkylating Agents
    • 4.2.3. Cyclophosphamide
    • 4.2.4. Others
  • 4.3. By Application
    • 4.3.1. Clinics
    • 4.3.2. Hospitals
    • 4.3.3. Others
  • 4.4. By Region
    • 4.4.1. North America
    • 4.4.2. South America
    • 4.4.3. Europe
    • 4.4.4. Asia-Pacific
    • 4.4.5. Middle East & Africa
  • 4.5. By Company Market Share (%), 2023

5. Global Idiopathic Membranous Nephropathy (IMN) Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Type
      • 5.1.2.1. Chlorambucil
      • 5.1.2.2. Alkylating Agents
      • 5.1.2.3. Cyclophosphamide
      • 5.1.2.4. Others
    • 5.1.3. By Application
      • 5.1.3.1. Clinics
      • 5.1.3.2. Hospitals
      • 5.1.3.3. Others
    • 5.1.4. United States*
      • 5.1.4.1. Market Size & Forecast
      • 5.1.4.1.1. By Value
      • 5.1.4.1.2. By Volume
      • 5.1.4.2. By Type
      • 5.1.4.2.1. Chlorambucil
      • 5.1.4.2.2. Alkylating Agents
      • 5.1.4.2.3. Cyclophosphamide
      • 5.1.4.2.4. Others
      • 5.1.4.3. By Application
      • 5.1.4.3.1. Clinics
      • 5.1.4.3.2. Hospitals
      • 5.1.4.3.3. Others
    • 5.1.5. Canada
    • 5.1.6. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Application
  • 6.3. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Novartis AG
  • 13.3. F. Hoffmann-La Roche Ltd
  • 13.4. Astellas Pharma Inc.
  • 13.5. GlaxoSmithKline
  • 13.6. Aspen Global Inc.
  • 13.7. Baxter Healthcare Corporation
  • 13.8. Mylan Pharmaceuticals Inc
  • 13.9. Sigma-Aldrich Corporation
  • 13.10. Merck & Co., Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer